Real-world outcomes of everolimus-based therapy after CDK4/6 inhibitor therapy in ER-positive/HER2-negative metastatic breast cancer: a multicenter registry-based study.
- DOI
- 10.1007/s12282-026-01931-7
- Published
- 2026 Nov 10
- Container
- Breast cancer (Tokyo, Japan)
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s12282-026-01931-7,
title = {Real-world outcomes of everolimus-based therapy after CDK4/6 inhibitor therapy in ER-positive/HER2-negative metastatic breast cancer: a multicenter registry-based study.},
author = {Kiyohara H and Hanamura T and Sagara Y and Miyashita M and Saji S and Niikura N},
year = {2026},
journal = {Breast cancer (Tokyo, Japan)},
doi = {10.1007/s12282-026-01931-7},
url = {https://doi.org/10.1007/s12282-026-01931-7}
}RIS
TY - JOUR TI - Real-world outcomes of everolimus-based therapy after CDK4/6 inhibitor therapy in ER-positive/HER2-negative metastatic breast cancer: a multicenter registry-based study. AU - Kiyohara H AU - Hanamura T AU - Sagara Y AU - Miyashita M AU - Saji S AU - Niikura N PY - 2026 JO - Breast cancer (Tokyo, Japan) DO - 10.1007/s12282-026-01931-7 UR - https://doi.org/10.1007/s12282-026-01931-7 ER -
APA
H, K., T, H., Y, S., M, M., S, S., & N, N. (2026). Real-world outcomes of everolimus-based therapy after CDK4/6 inhibitor therapy in ER-positive/HER2-negative metastatic breast cancer: a multicenter registry-based study.. Breast cancer (Tokyo, Japan). https://doi.org/10.1007/s12282-026-01931-7
Source records
- pubmed · retrieved 2026-11-11T00:07:57.682Z